{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:57:25Z","timestamp":1792241845458,"version":"4.4.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:00:00Z","timestamp":1615248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Resistance to next-generation anti-androgen enzalutamide (ENZ) constitutes a major challenge for the treatment of castration-resistant prostate cancer (CRPC). By performing genome-wide ChIP-seq profiling in ENZ-resistant CRPC cells we identify a set of androgen receptor (AR) binding sites with increased AR binding intensity (ARBS-gained). While ARBS-gained loci lack the canonical androgen response elements (ARE) and pioneer factor FOXA1 binding motifs, they are highly enriched with CpG islands and the binding sites of unmethylated CpG dinucleotide-binding protein CXXC5 and the partner TET2. RNA-seq analysis reveals that both CXXC5 and its regulated genes including\n                    <jats:italic>ID1<\/jats:italic>\n                    are upregulated in ENZ-resistant cell lines and these results are further confirmed in patient-derived xenografts (PDXs) and patient specimens. Consistent with the finding that ARBS-gained loci are highly enriched with H3K27ac modification, ENZ-resistant PCa cells, organoids, xenografts and PDXs are hyper-sensitive to NEO2734, a dual inhibitor of BET and CBP\/p300 proteins. These results not only reveal a noncanonical AR function in acquisition of ENZ resistance, but also posit a treatment strategy to target this vulnerability in ENZ-resistant CRPC.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-21860-7","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T06:04:59Z","timestamp":1615269899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["A noncanonical AR addiction drives enzalutamide resistance in prostate cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Yundong","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0319-0239","authenticated-orcid":false,"given":"Jacob J.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Fazli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jeffrey Karnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2348-0214","authenticated-orcid":false,"given":"Rafael","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2072-4826","authenticated-orcid":false,"given":"Liguo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liewei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Gleave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9749-8591","authenticated-orcid":false,"given":"Yuzhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-6413","authenticated-orcid":false,"given":"Haojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"21860_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701\u2013711 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"21860_CR2","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1093\/jnci\/93.22.1687","volume":"93","author":"ME Grossmann","year":"2001","unstructured":"Grossmann, M. E., Huang, H. & Tindall, D. J. Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl Cancer Inst. 93, 1687\u20131697 (2001).","journal-title":"J. Natl Cancer Inst."},{"key":"21860_CR3","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ccr.2011.09.001","volume":"20","author":"C Cai","year":"2011","unstructured":"Cai, C. et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20, 457\u2013471 (2011).","journal-title":"Cancer Cell"},{"key":"21860_CR4","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.cell.2008.01.018","volume":"132","author":"M Lupien","year":"2008","unstructured":"Lupien, M. et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132, 958\u2013970 (2008).","journal-title":"Cell"},{"key":"21860_CR5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nature10006","volume":"474","author":"D Wang","year":"2011","unstructured":"Wang, D. et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474, 390\u2013394 (2011).","journal-title":"Nature"},{"key":"21860_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995\u20132005 (2011).","journal-title":"N. Engl. J. Med."},{"key":"21860_CR7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187\u20131197 (2012).","journal-title":"N. Engl. J. Med."},{"key":"21860_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424\u2013433 (2014).","journal-title":"N. Engl. J. Med."},{"key":"21860_CR9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora, V. K. et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155, 1309\u20131322 (2013).","journal-title":"Cell"},{"key":"21860_CR10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028\u20131038 (2014).","journal-title":"N. Engl. J. Med."},{"key":"21860_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2019.01.008","volume":"35","author":"L Cato","year":"2019","unstructured":"Cato, L. et al. ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer. Cancer Cell 35, 401\u2013413 (2019). e406.","journal-title":"Cancer Cell"},{"key":"21860_CR12","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","volume":"3","author":"JD Joseph","year":"2013","unstructured":"Joseph, J. D. et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 3, 1020\u20131029 (2013).","journal-title":"Cancer Discov."},{"key":"21860_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cell.2018.05.037","volume":"174","author":"DY Takeda","year":"2018","unstructured":"Takeda, D. Y. et al. A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer. Cell 174, 422\u2013432 (2018). e413.","journal-title":"Cell"},{"key":"21860_CR14","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley, D. A. et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 174, 758\u2013769 (2018). e759.","journal-title":"Cell"},{"key":"21860_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2018.05.036","volume":"174","author":"SR Viswanathan","year":"2018","unstructured":"Viswanathan, S. R. et al. Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing. Cell 174, 433\u2013447 (2018). e419.","journal-title":"Cell"},{"key":"21860_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","volume":"32","author":"EG Bluemn","year":"2017","unstructured":"Bluemn, E. G. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32, 474\u2013489 (2017). e476.","journal-title":"Cancer Cell"},{"key":"21860_CR17","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1126\/science.aab0917","volume":"349","author":"DT Miyamoto","year":"2015","unstructured":"Miyamoto, D. T. et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science 349, 1351\u20131356 (2015).","journal-title":"Science"},{"key":"21860_CR18","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/s41591-018-0241-1","volume":"24","author":"M Rotinen","year":"2018","unstructured":"Rotinen, M. et al. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nat. Med. 24, 1887\u20131898 (2018).","journal-title":"Nat. Med."},{"key":"21860_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","volume":"7","author":"JL Bishop","year":"2017","unstructured":"Bishop, J. L. et al. The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer. Cancer Discov. 7, 54\u201371 (2017).","journal-title":"Cancer Discov."},{"key":"21860_CR20","doi-asserted-by":"publisher","first-page":"12315","DOI":"10.1073\/pnas.1922207117","volume":"117","author":"JJ Alumkal","year":"2020","unstructured":"Alumkal, J. J. et al. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc. Natl Acad. Sci. USA 117, 12315\u201312323 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21860_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06067-7","volume":"9","author":"Q Li","year":"2018","unstructured":"Li, Q. et al. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat. Commun. 9, 3600 (2018).","journal-title":"Nat. Commun."},{"key":"21860_CR22","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.1158\/1078-0432.CCR-19-1587","volume":"25","author":"DE Spratt","year":"2019","unstructured":"Spratt, D. E. et al. Transcriptomic heterogeneity of androgen receptor activity defines a de novo low AR-active subclass in treatment naive primary prostate cancer. Clin. Cancer Res. 25, 6721\u20136730 (2019).","journal-title":"Clin. Cancer Res."},{"key":"21860_CR23","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque, M. P. et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J. Clin. Investig. 129, 4492\u20134505 (2019).","journal-title":"J. Clin. Investig."},{"key":"21860_CR24","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.cell.2016.09.018","volume":"167","author":"HK Long","year":"2016","unstructured":"Long, H. K., Prescott, S. L. & Wysocka, J. Ever-changing landscapes: transcriptional enhancers in development and evolution. Cell 167, 1170\u20131187 (2016).","journal-title":"Cell"},{"key":"21860_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature11279","volume":"489","author":"A Sanyal","year":"2012","unstructured":"Sanyal, A., Lajoie, B. R., Jain, G. & Dekker, J. The long-range interaction landscape of gene promoters. Nature 489, 109\u2013113 (2012).","journal-title":"Nature"},{"key":"21860_CR26","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1126\/science.1260943","volume":"347","author":"SK Reilly","year":"2015","unstructured":"Reilly, S. K. et al. Evolutionary genomics. Evolutionary changes in promoter and enhancer activity during human corticogenesis. Science 347, 1155\u20131159 (2015).","journal-title":"Science"},{"key":"21860_CR27","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1093\/nar\/gkr574","volume":"39","author":"JE Reid","year":"2011","unstructured":"Reid, J. E. & Wernisch, L. STEME: efficient EM to find motifs in large data sets. Nucleic Acids Res. 39, e126 (2011).","journal-title":"Nucleic Acids Res."},{"key":"21860_CR28","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1101\/gad.2037511","volume":"25","author":"AM Deaton","year":"2011","unstructured":"Deaton, A. M. & Bird, A. CpG islands and the regulation of transcription. Genes Dev. 25, 1010\u20131022 (2011).","journal-title":"Genes Dev."},{"key":"21860_CR29","doi-asserted-by":"publisher","first-page":"10765","DOI":"10.1093\/nar\/gks888","volume":"40","author":"KF Decker","year":"2012","unstructured":"Decker, K. F. et al. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res. 40, 10765\u201310779 (2012).","journal-title":"Nucleic Acids Res."},{"key":"21860_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.str.2017.11.022","volume":"26","author":"C Xu","year":"2018","unstructured":"Xu, C. et al. DNA sequence recognition of human CXXC domains and their structural determinants. Structure 26, 85\u201395 (2018). e83.","journal-title":"Structure"},{"key":"21860_CR31","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1042\/BST20130028","volume":"41","author":"HK Long","year":"2013","unstructured":"Long, H. K., Blackledge, N. P. & Klose, R. J. ZF-CxxC domain-containing proteins, CpG islands and the chromatin connection. Biochem. Soc. Trans. 41, 727\u2013740 (2013).","journal-title":"Biochem. Soc. Trans."},{"key":"21860_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nature12052","volume":"497","author":"M Ko","year":"2013","unstructured":"Ko, M. et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature 497, 122\u2013126 (2013).","journal-title":"Nature"},{"key":"21860_CR33","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1084\/jem.20161149","volume":"214","author":"S Ma","year":"2017","unstructured":"Ma, S. et al. Epigenetic regulator CXXC5 recruits DNA demethylase Tet2 to regulate TLR7\/9-elicited IFN response in pDCs. J. Exp. Med. 214, 1471\u20131491 (2017).","journal-title":"J. Exp. Med."},{"key":"21860_CR34","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/44334","volume":"401","author":"D Lyden","year":"1999","unstructured":"Lyden, D. et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401, 670\u2013677 (1999).","journal-title":"Nature"},{"key":"21860_CR35","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ccr.2012.04.036","volume":"21","author":"CA O\u2019Brien","year":"2012","unstructured":"O\u2019Brien, C. A. et al. ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell 21, 777\u2013792 (2012).","journal-title":"Cancer Cell"},{"key":"21860_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.stem.2009.08.017","volume":"5","author":"HS Nam","year":"2009","unstructured":"Nam, H. S. & Benezra, R. High levels of Id1 expression define B1 type adult neural stem cells. Cell Stem Cell 5, 515\u2013526 (2009).","journal-title":"Cell Stem Cell"},{"key":"21860_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9230","volume":"6","author":"YN Tang","year":"2015","unstructured":"Tang, Y. N. et al. Epigenetic regulation of Smad2 and Smad3 by profilin-2 promotes lung cancer growth and metastasis. Nat. Commun. 6, 8230 (2015).","journal-title":"Nat. Commun."},{"key":"21860_CR38","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1038\/sj.emboj.7601737","volume":"26","author":"P Pilo Boyl","year":"2007","unstructured":"Pilo Boyl, P. et al. Profilin2 contributes to synaptic vesicle exocytosis, neuronal excitability, and novelty-seeking behavior. EMBO J. 26, 2991\u20133002 (2007).","journal-title":"EMBO J."},{"key":"21860_CR39","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S1535-6108(02)00209-X","volume":"2","author":"OV Volpert","year":"2002","unstructured":"Volpert, O. V. et al. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2, 473\u2013483 (2002).","journal-title":"Cancer Cell"},{"key":"21860_CR40","doi-asserted-by":"publisher","first-page":"13543","DOI":"10.1073\/pnas.2230238100","volume":"100","author":"S Fong","year":"2003","unstructured":"Fong, S. et al. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc. Natl Acad. Sci. USA 100, 13543\u201313548 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21860_CR41","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA 116, 11428\u201311436 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21860_CR42","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1021\/acsmedchemlett.6b00075","volume":"7","author":"AM Taylor","year":"2016","unstructured":"Taylor, A. M. et al. Fragment-based discovery of a selective and cell-active benzodiazepinone CBP\/EP300 bromodomain inhibitor (CPI-637). ACS Med. Chem. Lett. 7, 531\u2013536 (2016).","journal-title":"ACS Med. Chem. Lett."},{"key":"21860_CR43","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature13229","volume":"510","author":"IA Asangani","year":"2014","unstructured":"Asangani, I. A. et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278\u2013282 (2014).","journal-title":"Nature"},{"key":"21860_CR44","doi-asserted-by":"crossref","unstructured":"Giles, F., Witcher, M., Brown, B. NEO2734: a novel potent oral dual BET and P300\/CBP inhibitor. Ann. Oncol. 29(suppl 8), viii140\u2013viii141 (2018).","DOI":"10.1093\/annonc\/mdy279.416"},{"key":"21860_CR45","doi-asserted-by":"publisher","first-page":"e0145176","DOI":"10.1371\/journal.pone.0145176","volume":"10","author":"M Kohli","year":"2015","unstructured":"Kohli, M. et al. Mutational landscapes of sequential prostate metastases and matched patient derived xenografts during enzalutamide therapy. PloS ONE 10, e0145176 (2015).","journal-title":"PloS ONE"},{"key":"21860_CR46","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298\u2013305 (2016).","journal-title":"Nat. Med."},{"key":"21860_CR47","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nm.4053","volume":"22","author":"A Kumar","year":"2016","unstructured":"Kumar, A. et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat. Med. 22, 369\u2013378 (2016).","journal-title":"Nat. Med."},{"key":"21860_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08133-6","volume":"10","author":"H Guo","year":"2019","unstructured":"Guo, H. et al. ONECUT2 is a driver of neuroendocrine prostate cancer. Nat. Commun. 10, 278 (2019).","journal-title":"Nat. Commun."},{"key":"21860_CR49","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1172\/JCI127961","volume":"129","author":"A Berger","year":"2019","unstructured":"Berger, A. et al. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J. Clin. Investig. 129, 3924\u20133940 (2019).","journal-title":"J. Clin. Investig."},{"key":"21860_CR50","doi-asserted-by":"publisher","first-page":"e10659","DOI":"10.15252\/emmm.201910659","volume":"11","author":"Y Yan","year":"2019","unstructured":"Yan, Y. et al. The novel BET-CBP\/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. EMBO Mol. Med. 11, e10659 (2019).","journal-title":"EMBO Mol. Med."},{"key":"21860_CR51","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1158\/1535-7163.MCT-20-0087","volume":"19","author":"CD Morrison-Smith","year":"2020","unstructured":"Morrison-Smith, C. D. et al. Combined targeting of the BRD4-NUT-p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734. Mol. Cancer Ther. 19, 1406\u20131414 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"21860_CR52","doi-asserted-by":"publisher","unstructured":"Ryan, K. R., Giles, F., Morgan, G. J. Targeting both BET and CBP\/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma. Eur. J. Haematol., (2020). https:\/\/doi.org\/10.1111\/ejh.13525.","DOI":"10.1111\/ejh.13525"},{"key":"21860_CR53","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/nar\/gkx1306","volume":"46","author":"Y He","year":"2018","unstructured":"He, Y. et al. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. Nucleic Acids Res. 46, 1895\u20131911 (2018).","journal-title":"Nucleic Acids Res."},{"key":"21860_CR54","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.cell.2009.12.002","volume":"139","author":"JC Peng","year":"2009","unstructured":"Peng, J. C. et al. Jarid2\/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell 139, 1290\u20131302 (2009).","journal-title":"Cell"},{"key":"21860_CR55","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"21860_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).","journal-title":"Genome Biol."},{"key":"21860_CR57","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.1630","volume":"28","author":"CY McLean","year":"2010","unstructured":"McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495\u2013501 (2010).","journal-title":"Nat. Biotechnol."},{"key":"21860_CR58","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576\u2013589 (2010).","journal-title":"Mol. Cell"},{"key":"21860_CR59","doi-asserted-by":"publisher","first-page":"e90735","DOI":"10.1371\/journal.pone.0090735","volume":"9","author":"JE Reid","year":"2014","unstructured":"Reid, J. E. & Wernisch, L. STEME: a robust, accurate motif finder for large data sets. PLoS ONE 9, e90735 (2014).","journal-title":"PLoS ONE"},{"key":"21860_CR60","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"key":"21860_CR61","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21860_CR62","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"21860_CR63","doi-asserted-by":"publisher","first-page":"13122","DOI":"10.1038\/ncomms13122","volume":"7","author":"Y He","year":"2016","unstructured":"He, Y. et al. Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer. Nat. Commun. 7, 13122 (2016).","journal-title":"Nat. Commun."},{"key":"21860_CR64","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nprot.2016.006","volume":"11","author":"J Drost","year":"2016","unstructured":"Drost, J. et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat. Protoc. 11, 347\u2013358 (2016).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21860-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21860-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21860-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T06:04:23Z","timestamp":1669961063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21860-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21860"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21860-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]},"assertion":[{"value":"7 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1521"}}